• Endo Pharmaceuticals Inc., of Malvern, Pa., and Biodelivery Sciences International Inc., of Raleigh, N.C., completed interim analysis in a Phase III trial of BEMA Buprenorphine. Read More
• Tris Pharma Inc., of Monmouth Junction, N.J., and FSC Laboratories Inc., of Charlotte, N.C., signed a license agreement for commercialization of Karbinal ER (carbinoxamine maleate) extended-release oral suspension, a sustained-release histamine receptor blocking agent for allergic rhinitis in children 2 and older. Read More
• Ariad Pharmaceuticals Inc., of Cambridge, Mass., said it reached enrollment of 50 percent of the patients planned in its randomized Phase III trial of Iclusig (ponatinib) in adults with newly diagnosed chronic myeloid leukemia (CML). Read More
• Globeimmune Inc., of Louisville, Colo., said it was awarded a research project grant of $4 million from the National Institute of Allergy and Infectious Diseases to support the development of Tarmogen immunotherapy products to treat and prevent tuberculosis infection. Read More
MUNICH, Germany – Shares in Wilex AG gained as much as 12 percent Monday on news that its subsidiary, Heidelberg Pharma GmbH, entered a research collaboration and option agreement with Roche Holding AG, based on its preclinical antibody-drug conjugate (ADC) technology. Read More
Former Dendreon Corp. CEO Mitch Gold and investment analyst David Miller have teamed up to open a new Seattle-based hedge fund, Alpine BioVentures. The multimillion-dollar fund will invest in newer companies in the biotech space, particularly in the area of cancer and rare diseases. Read More
Armed with a $30 million financing, privately held Ipierian Inc. took the bold move of launching spinout True North Therapeutics, with a portion of the funds serving as the newco’s Series A. Read More
Otonomy Inc.’s $45.9 million Series C round should last the firm into the second half of 2014, when one of its ear disease drugs is expected to be ready for a new drug application filing, another will have finished the first of a pair of pivotal trials and a third will be eligible for an investigational new drug application. Read More
